Entecavir as a first-line treatment for hepatitis B virus reactivation following polychemotherapy for chronic lymphocytic leukemia and invasive ductal carcinoma

Turker, Kamuran; Albayrak, Murat; Öksüzoğlu, Berna; Balc, Elçin; Oğan, Mustafa Cihat; İskender, Gülşen; Altuntaş, Fevzi

doi:10.1097/meg.0000000000000115

Cited by 6 publications

(7 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A previous study revealed that administration of an anti‐HBV drug, lamivudine, to NPC patients receiving chemotherapy, can reduce the incidences of HBV reactivation and chemotherapy‐related hepatitis . Studies on other types of tumors also revealed that antiviral therapy can reduce the incidence of HBV reactivation . Our results showed that the no‐antivirus group had 3 patients with liver injuries higher than grade 1, whereas no patient had liver injuries higher than grade 1 in the antivirus group; however, no statistically significant difference existed between the two groups.…”

Section: Discussioncontrasting

confidence: 40%

Effects of hepatitis B virus infection and antiviral therapy on the clinical prognosis of nasopharyngeal carcinoma

Weng

Wei

et al. 2019

Cancer Medicine

View full text Add to dashboard Cite

Purpose: To investigate the clinical characteristics of nasopharyngeal carcinoma (NPC) and a concomitant hepatitis B virus (HBV) infection, as well as the potential effects of HBV infection and antiviral therapy on prognosis. Methods: We conducted a retrospective chart review of all NPC patients from December 2010 to December 2014. After collecting medical records and conducting follow-ups on patients, a total of 876 eligible NPC patients were included. For each patient, medical records were reviewed. Factors predictive of outcome were compared using the log-rank test and Cox regression analysis. Results: Among the 876 participants, 106 (12.1%) patients were HBV-infected patients. The hepatitis B surface antigen-positive [HBsAg(+)] group had a lower CD 4+ T cell count than the HBsAg(−) group (P = .048). Among patients with stage I/II NPC, 5-year overall survival (OS), disease-free survival (DFS), relapse-free survival, and distant metastasis-free survival (DMFS) of the HBsAg(+) group were 82.5%, 70.7%, 87.7%, and 76.6%, respectively, whereas those of the HBsAg(−) group were 91.4%, 86.0%, 93.8%, and 92.1%, respectively. Statistically significant differences in OS, DFS, and DMFS existed between both groups (P = .017, .018, and .004, respectively). The multivariate analysis indicated that HBsAg status and N stage are independent risk factors affecting OS, DFS, and DMFS of NPC patients. A statistically significant difference in 5-year DMFS existed between the antivirus (90.0%) and no-antivirus groups (70.0%) (P = .043). Conclusions: Hepatitis B virus infection is an independent risk factor for early stage NPC, which may be associated with its reduced immune functions compared to the HBsAg(−) group. Anti-HBV treatment may improve the prognosis of HBV-infected NPC patients. K E Y W O R D S antiviral therapy, hepatitis B virus, nasopharyngeal carcinoma, prognosis 542 | WENG Et al.

show abstract

Section: Discussioncontrasting

confidence: 40%

Effects of hepatitis B virus infection and antiviral therapy on the clinical prognosis of nasopharyngeal carcinoma

Weng

Wei

et al. 2019

Cancer Medicine

View full text Add to dashboard Cite

show abstract

“…Only a retrospective study [40] and two case series [41,42] described successful treatment with drugs with higher antiviral potency and high genetic barrier, such as entecavir or tenofovir, in haematologic patients.…”

Section: Hbv-negative Allo-hsct Recipient With An Anti-hbv-positive Dmentioning

confidence: 99%

Recommendations for screening, monitoring, prevention, prophylaxis and therapy of hepatitis B virus reactivation in patients with haematologic malignancies and patients who underwent haematologic stem cell transplantation—a position paper

Sarmati

Andreoni

Antonelli

et al. 2017

Clinical Microbiology and Infection

View full text Add to dashboard Cite

Haematologic patients should be screened for hepatitis B surface antigen (HBsAg) plus anti-hepatitis B core protein (HBc), and HBV DNA before chemotherapy. HBV DNA levels should be monitored monthly in all HBV-positive patients who do not receive prophylaxis. HBsAg-positive haematologic patients and those undergoing HSCT should receive third-generation antiviral therapy as prophylaxis. Anti-HBc-positive lymphoma patients and those receiving HSCT should receive antiviral prophylaxis. All HBV-negative haematologic patients should be vaccinated for HBV. The acquisition of data from well-designed studies is desirable in the near future.

show abstract

“…Numerous case reports and series describe death due to liver failure despite the introduction of lamivudine at the onset of HBV reactivation [ 124 - 128 ]. Only a few cases of successful treatment of HBV reactivation with entecavir or tenofovir have been published [ 42 , 129 - 131 ]. Despite the paucity of data regarding the efficacy of entecavir and tenofovir to treat established HBV reactivation, the ability of these drugs to rapidly reduce HBV DNA make them attractive alternatives to lamivudine in patients who experience HBV reactivation to potentially abrogate the risk of liver failure and mortality.…”

Section: How Do We Manage Hepatitis B Reactivation?mentioning

confidence: 99%

Prevention of Hepatitis B reactivation in the setting of immunosuppression

Pattullo

2016

Clin Mol Hepatol

113

View full text Add to dashboard Cite

Advances in the treatment of malignant and inflammatory diseases have developed over time, with increasing use of chemotherapeutic and immunosuppressive agents of a range of drug classes with varying mechanism and potency in their effects on the immune system. These advances have been met with the challenge of increased risk of hepatitis B virus (HBV) reactivation in susceptible individuals. The magnitude of risk of HBV reactivation is associated with the individual’s HBV serological status and the potency and duration of immunosuppression. Individuals with chronic hepatitis B (CHB) and previously infected but serologically cleared HBV infection are both susceptible to HBV reactivation. HBV reactivation in the setting of immunosuppression is a potentially life threatening condition leading to liver failure and death in extreme cases. It is important to recognize that HBV reactivation in the setting of immunosuppression is potentially preventable. Therefore, identification of patients at risk of HBV reactivation and institution of prophylactic antiviral therapy prior to initiation of immunosuppression is essential.

show abstract

Entecavir as a first-line treatment for hepatitis B virus reactivation following polychemotherapy for chronic lymphocytic leukemia and invasive ductal carcinoma

Cited by 6 publications

References 34 publications

Effects of hepatitis B virus infection and antiviral therapy on the clinical prognosis of nasopharyngeal carcinoma

Effects of hepatitis B virus infection and antiviral therapy on the clinical prognosis of nasopharyngeal carcinoma

Recommendations for screening, monitoring, prevention, prophylaxis and therapy of hepatitis B virus reactivation in patients with haematologic malignancies and patients who underwent haematologic stem cell transplantation—a position paper

Prevention of Hepatitis B reactivation in the setting of immunosuppression

Contact Info

Product

Resources

About